Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Laura de Girolamo; Enrico Lucarelli; Giulio Alessandri; Maria Antonietta Avanzini; Maria Ester Bernardo; Ettore Biagi; Anna Teresa Brini; Giovanna D'Amico; Franca Fagioli; Ivana Ferrero; Franco Locatelli; Rita Maccario; Mario Marazzi; Ornella Parolini; Augusto Pessina; Maria Luisa Torre

doi:10.2174/1381612811319130015

Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D'Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina, Maria Luisa Torre

Research output: Contribution to journal › Article › peer-review

163 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

Original language	English (US)
Pages (from-to)	2459-2473
Number of pages	15
Journal	Current Pharmaceutical Design
Volume	19
Issue number	13
DOIs	https://doi.org/10.2174/1381612811319130015
State	Published - 2013

Keywords

Advanced therapy medicinal product
Cell therapy
Graft versus host disease
Immunomodulatory properties
MSCs sources
Mesenchymal stem/stromal cells
Regenerative medicine
Transplantation

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.2174/1381612811319130015

Cite this

de Girolamo, L., Lucarelli, E., Alessandri, G., Avanzini, M. A., Bernardo, M. E., Biagi, E., Brini, A. T., D'Amico, G., Fagioli, F., Ferrero, I., Locatelli, F., Maccario, R., Marazzi, M., Parolini, O., Pessina, A., & Torre, M. L. (2013). Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy. Current Pharmaceutical Design, 19(13), 2459-2473. https://doi.org/10.2174/1381612811319130015

de Girolamo, L, Lucarelli, E, Alessandri, G, Avanzini, MA, Bernardo, ME, Biagi, E, Brini, AT, D'Amico, G, Fagioli, F, Ferrero, I, Locatelli, F, Maccario, R, Marazzi, M, Parolini, O, Pessina, A & Torre, ML 2013, 'Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy', Current Pharmaceutical Design, vol. 19, no. 13, pp. 2459-2473. https://doi.org/10.2174/1381612811319130015

@article{ff0f53364ba542829ad4859343fb8a6b,

title = "Mesenchymal stem/stromal cells: A new {"}cells as drugs{"} paradigm. efficacy and critical aspects in cell therapy",

abstract = "Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.",

keywords = "Advanced therapy medicinal product, Cell therapy, Graft versus host disease, Immunomodulatory properties, MSCs sources, Mesenchymal stem/stromal cells, Regenerative medicine, Transplantation",

author = "\{de Girolamo\}, Laura and Enrico Lucarelli and Giulio Alessandri and Avanzini, \{Maria Antonietta\} and Bernardo, \{Maria Ester\} and Ettore Biagi and Brini, \{Anna Teresa\} and Giovanna D'Amico and Franca Fagioli and Ivana Ferrero and Franco Locatelli and Rita Maccario and Mario Marazzi and Ornella Parolini and Augusto Pessina and Torre, \{Maria Luisa\}",

year = "2013",

doi = "10.2174/1381612811319130015",

language = "English (US)",

volume = "19",

pages = "2459--2473",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers Ltd.",

number = "13",

}

TY - JOUR

T1 - Mesenchymal stem/stromal cells

T2 - A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

AU - de Girolamo, Laura

AU - Lucarelli, Enrico

AU - Alessandri, Giulio

AU - Avanzini, Maria Antonietta

AU - Bernardo, Maria Ester

AU - Biagi, Ettore

AU - Brini, Anna Teresa

AU - D'Amico, Giovanna

AU - Fagioli, Franca

AU - Ferrero, Ivana

AU - Locatelli, Franco

AU - Maccario, Rita

AU - Marazzi, Mario

AU - Parolini, Ornella

AU - Pessina, Augusto

AU - Torre, Maria Luisa

PY - 2013

Y1 - 2013

N2 - Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

AB - Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

KW - Advanced therapy medicinal product

KW - Cell therapy

KW - Graft versus host disease

KW - Immunomodulatory properties

KW - MSCs sources

KW - Mesenchymal stem/stromal cells

KW - Regenerative medicine

KW - Transplantation

UR - https://www.scopus.com/pages/publications/84877820900

UR - https://www.scopus.com/inward/citedby.url?scp=84877820900&partnerID=8YFLogxK

U2 - 10.2174/1381612811319130015

DO - 10.2174/1381612811319130015

M3 - Article

C2 - 23278600

AN - SCOPUS:84877820900

SN - 1381-6128

VL - 19

SP - 2459

EP - 2473

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 13

ER -

Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this